A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment
NCT ID: NCT00934375
Last Updated: 2014-01-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
145 participants
INTERVENTIONAL
2006-02-28
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment
NCT00103948
The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
NCT00293176
A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI
NCT00483028
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
NCT00096473
Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease
NCT00165737
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Aricept (donepezil hydrochloride)
5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
2
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aricept (donepezil hydrochloride)
5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Sex distribution: Men and women. Women of child-bearing potential (\<1 year post menopausal) must be practicing effective contraception and have negative serum B-HCG at Screening. \[Women who are breast-feeding are excluded.\]
3. Subjects must have completed the one year, double-blind core trial (E2020-A001-412).
4. A completed Diagnostic Worksheet at the end of the double-blind core trial (E2020-A001-412) indicating no conversion to Alzheimer's Disease or dementia.
5. Health: Generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane).
6. The subject must be expected to complete the entire study.
7. Subjects must be sufficiently fluent in English.
8. Subjects must have an informant who has daily contact with the subject (e.g., an average of 10 or more hours per week), can observe for possible adverse events and will accompany the subject to all visits.
9. Clinical laboratory values must be within normal limits, or if abnormal, judged clinically insignificant by the investigator (not likely to cause cognitive impairment or medical instability).
Exclusion Criteria
2. Any subject without a completed diagnostic worksheet from Week 51 of the core double-blind trial (E2020-A001-412).
3. Any subject with a completed diagnostic worksheet from Week 51 of the core double-blind trial (E2020-A001-412) indicating conversion to Alzheimer's or other dementia.
4. Subjects with uncontrolled hypertension (sitting systolic \>= 160mmHg and/or diastolic \>=95mmHg) as assessed by the investigator, regardless of whether or not the subject is taking anti-hypertensive medications.
5. Subjects with a history of malignant neoplasms treated within five years prior to study entry (other than basal or squamous cell carcinoma of the skin); current evidence of malignant neoplasm; or recurrent or matastatic disease.
6. Subjects who have suffered a severe infection or a major surgical procedure within three months prior to baseline.
7. Subjects who may not be able to comply with the protocol.
8. Subjects with known hypersensitivity to piperidine derivatives or acetylcholinesterase(AChE)inhibitors.
9. Subjects with diabetes mellitis not controlled by diet and/or medication with a random serum glucose value of \>170mg/dl.
10. Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study.
11. Subjects who do not have a reliable informant (e.g., the informant has contact with the subject less than 10 hours per week).
45 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eisai Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anita Murthy
Role: STUDY_DIRECTOR
Eisai Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neurology Neurodiagnostic Lab, LLC
Alabaster, Alabama, United States
Pivotal Research Centers
Peoria, Arizona, United States
Sun Health Research Institute
Sun City, Arizona, United States
Northwest Neurospecialists, PLLC
Tucson, Arizona, United States
The Neurology Center
Encinitas, California, United States
Margolin Brain Institute
Fresno, California, United States
Colaborative Neuroscience Network (CNS Network)
Garden Grove, California, United States
Nerve Pro Research
Irvine, California, United States
Optimum Health Services
La Mesa, California, United States
Pacific Research Network
San Diego, California, United States
Neurological Research Institute
Santa Monica, California, United States
CA Neuroscience Research
Sherman Oaks, California, United States
Pacific Research Network
Vista, California, United States
Yale University Alzheimers Disease Research Unit School of Medicine Department of Psychiatry
New Haven, Connecticut, United States
North Broward Medical Center Memory Disorder Center
Deerfield Beach, Florida, United States
Neurologic Consultants
Fort Lauderdale, Florida, United States
Berma Research Group
Hialeah, Florida, United States
Sunrise Clinical Research
Hollywood, Florida, United States
Wien Center for Memory Disorders, Mount Sinai Medical Center
Miami Beach, Florida, United States
Berma Research Group
Plantation, Florida, United States
The Roskamp Institute
Sarasota, Florida, United States
Comprehensive Neuroscience, Inc.
St. Petersburg, Florida, United States
Stedman Clinical Trials, LLC
Tampa, Florida, United States
USF Memory Disorder's Clinic
Tampa, Florida, United States
USF Suncoast Gerontalogy Center
Tampa, Florida, United States
Center for Clinical Trials. L.C.
Venice, Florida, United States
Palm Beach Neurology
West Palm Beach, Florida, United States
Lexington Clinic
Lexington, Kentucky, United States
Borgess Research Institute
Kalamazoo, Michigan, United States
St. Louis University - Clinical Trials Unit
St Louis, Missouri, United States
Comprehensive Neuroscience, Inc
Kenilworth, New Jersey, United States
Neurological Associates of Albany, PC Neurology
Albany, New York, United States
Neurobehavioral Research Inc.
Lawrence, New York, United States
New York University School of Medicine Aging and Dementia Research Center
New York, New York, United States
Columbia University
New York, New York, United States
Monroe Community Hospital Program in Neurobehavioral Therapeutics
Rochester, New York, United States
Behavioral Medical Research of Staten Island
Staten Island, New York, United States
The Ohio State University
Columbus, Ohio, United States
Neurology Center of Ohio
Toledo, Ohio, United States
Pahl Pharmaceutical Research, LLC
Oklahoma City, Oklahoma, United States
Summit Research Network(Oregon) Inc.
Portland, Oregon, United States
Clinical Trial Specialists
Bala-Cynwyd, Pennsylvania, United States
Westmoreland Neurology Associates
Greensburg, Pennsylvania, United States
The Clinical Trial Center, LLC
Jenkintown, Pennsylvania, United States
Medical University of South Carolina-Alzheimer's Research
Charleston, South Carolina, United States
The University of Texas Mental Sciences Instittute
Houston, Texas, United States
START Center
San Antonio, Texas, United States
Grayline Clinical Drug Trials
Wichita Falls, Texas, United States
Southwestern Vermont Medical Center - The Memory Clinc
Bennington, Vermont, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E2020-A001-414
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.